Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Taletrectinib Under NMPA Review in China for First-Line ROS1+ NSCLC

March 5th 2024

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

Levy Delves Into the Evolution of ADCs in NSCLC

March 4th 2024

Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.

FDA Lifts Clinical Hold on Trial Investigating LN-145 in NSCLC

March 4th 2024

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

EMA Validates MAAs for Datopotamab Deruxtecan in NSCLC and HR+ Breast Cancer

March 4th 2024

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.

Dr Mohindra on Updates in SCLC Management

March 1st 2024

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

FDA Approves Frontline Amivantamab Plus Chemo for EGFR Exon 20 Insertion+ NSCLC

March 1st 2024

The FDA has approved amivantamab plus chemotherapy for the frontline treatment of select patients with EGFR exon 20 insertion+ non–small cell lung cancer.

Molecular Correlates May Be Key in Unleashing the Full Potential of Immunotherapy in NSCLC

February 29th 2024

Ashish Saxena, MD, PhD, discusses the movement of targeted and immune therapies in non–small cell lung cancer treatment.

FDA Approval Highlights: OncLive’s February Recap

February 29th 2024

In case you missed it, below is a recap of all drugs that have been approved by the FDA in February 2024.

Dr Baldonado on the Evolution of Targeted Therapy in NSCLC

February 28th 2024

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.

Osimertinib Plus Chemo Adds Combination Strategy to Advanced EGFR+ NSCLC Armamentarium

February 28th 2024

Pasi A. Jänne, MD, PhD discusses the FDA approval of osimertinib plus chemotherapy for patients with EGFR-positive non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to NVL-520 for Metastatic ROS1+ NSCLC

February 27th 2024

The FDA has granted breakthrough therapy designation to NVL-520 for pretreated, metastatic ROS1-positive non–small cell lung cancer.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study

February 26th 2024

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

Tislelizumab Receives CHMP Recommendation for First- and Second-Line Treatment of NSCLC

February 26th 2024

The European Medicines Agency’s CHMP has recommended the approval of tislelizumab in the first- and second-line for non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to BAY 2927088 for HER2-Mutated NSCLC

February 26th 2024

BAY 2927088 has received breakthrough therapy designation by the FDA for pretreated non–small cell lung cancer harboring activating HER2 mutations.

Perioperative Pembrolizumab Regimen Receives Positive CHMP Opinion in NSCLC

February 23rd 2024

Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.

Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLC

February 23rd 2024

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Dr Punekar on the Importance of Complete Biomarker Testing in Lung Cancer

February 22nd 2024

Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.

Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLC

February 21st 2024

Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.

Lurbinectedin Displays Superior Risk/Benefit Ratio Over Topotecan in SCLC

February 20th 2024

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.